Business Wire

Promega Expands Forensic Portfolio with Distribution Agreement for NimaGen’s IDseek® MPS Library Prep Kits

14.4.2026 13:01:00 CEST | Business Wire | Press release

Share

Agreement adds STR, SNP, microhaplotype and mitochondrial DNA MPS kits to Promega forensic product lineup

Forensic casework laboratories will now have access to NimaGen’s IDseek® massively parallel sequencing (MPS) kit portfolio through Promega Corporation, following a distribution agreement announced today between the two companies. The IDseek® line is powered by NimaGen’s patented Reverse Complement PCR (RC-PCR) technology to deliver the sensitivity and specificity required for challenging casework samples. These sequencing kits extend the existing Promega portfolio of sample preparation and capillary electrophoresis (CE)-based STR analysis tools.

“For decades, we have anticipated and responded to the technologies that forensic laboratories need to produce reliable results,” says Tim Kupferschmid, Senior Director of Genetic Identity at Promega. “With this agreement, labs that have long benefited from Promega reagents, instrumentation and support can continue relying on us as they expand their workflows with massively parallel sequencing.”

IDseek® Massively Parallel Sequencing (MPS) Kits

All IDseek® library prep kits are built on RC-PCR technology, which enables forensic MPS library preparation in a single closed-tube reaction. The workflow is designed for the sensitivity demands of forensic casework, including degraded and low-quantity samples, and produces high on-target read yields that maximize sequencing efficiency.

“This marks an important milestone in our growth, extending our sales reach and deepening our technical capabilities to better serve customers around the world,” says Pieter van Oers, Senior Manager of Business Development – Forensics at NimaGen. “Our RC-PCR library preparation technology fundamentally simplifies the MPS workflow, eliminating the complexity that has prevented many laboratories from transitioning to MPS. With our IDseek® MPS library prep portfolio, forensic scientists can now access the power of MPS with a workflow that resembles traditional CE methods, while increasing sample safety, sensitivity and discrimination power of forensic STR testing.”

Under the new agreement, Promega will distribute more than 20 products across seven product families. Examples of applications supported include:

  • Autosomal STR profiling (IDseek® OmniSTR™)
  • Y-chromosomal STR profiling (IDseek® mYSTR™)
  • Autosomal and Y-chromosomal STR profiling (IDseek® CombiSTR™ Plus)
  • Microhaplotype analysis (IDseek® OmniHAP™)
  • Identity informative SNP typing (IDseek® OmniSNP™)
  • Mitochondrial DNA sequencing (IDseek® Mitochondrial HVR and Full Genome kits)

Promega Support for Forensic Laboratories

Promega has supported forensic laboratories for more than 30 years with products, instrumentation and technical expertise spanning the full workflow of human identification. For forensic laboratories evaluating the transition to MPS-based workflows, the ability to access NimaGen’s IDseek® portfolio through an established Promega relationship simplifies the path to MPS adoption. The Promega global distribution network, forensic-specific technical support infrastructure and decades of experience serving casework laboratories mean that laboratories can move into MPS with the same supplier accountability they already rely on for their CE-based workflows.

To learn more about IDseek® products distributed by Promega, click here

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com

About NimaGen

NimaGen B.V. is a biotechnology company specializing in innovative DNA sequencing technologies for forensic applications and human identification. Headquartered in Nijmegen, The Netherlands, NimaGen holds the exclusive license for the patented Reverse Complement PCR (RC-PCR) technology, granted by the Salisbury NHS Foundation Trust, United Kingdom. The company's IDseek® product line represents the next revolution in forensic MPS, combining unmatched sensitivity, robustness, and sample safety with simplified workflows that make advanced sequencing accessible to forensic laboratories worldwide. NimaGen is part of Biolegio Holding.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260413426143/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release

Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release

QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye